Rational discovery of new medicines, be it traditional smallmolecule drugs or biologics such as antibodies, is a major field of paramount importance. University-based research in Flanders plays a key role here, being able to explore novel directions, high-risk opportunities and clinically unmet needs. The rational approach requires the knowledge of the three-dimensional structure of the given drug target (usually a protein). In addition, ...
Employing state-of-the-art simulation and drug design techniques in search for the structure, mechanism and small-molecule modulators of the Cystine/Glutamate Antiporter system xc− Vrije Universiteit Brussel
Numerical Modeling of the Drug Carrier Transport for Targeted Drug Delivery in Liver Cancer Ghent University
The goal of the project is to explore the added value of computational models to
optimize targeted drug delivery for unresectable liver cancer. Patient-/rat-specific 3D computational fluid dynamics models of the blood circulation and drug transport in the liver will be developed. The envisaged project may reveal new possibilities to manipulate the drug distribution and maximally affect tumorous tissue.
Rationally designed drug combination screen in more physiologically relevant in vitro organoid models: can we improve personalized therapy for pancreatic cancer? University of Antwerp
Design and pre-clincial evaluation of self-replicating mRNA therapeutics that produce protein drugs under control of small, non-toxic molecules Ghent University
Protein drugs have become a standard treatment for an increasing number of severe diseases. However, the complex and labor-intensive production process makes protein drugs very costly. Therefore, therapeutic proteins cause a considerable burden to our social security system. A possible solution is to enable patients to produce their own therapeutic proteins. This can be achieved by using synthetic messenger RNAs (mRNAs). In our body millions ...
FWO-SB-Beurs: Unraveling the structure, function and molecular mechanisms of TBCID24, a new target for drug development against epilepsy and related disorders Vrije Universiteit Brussel
An ontogenic pig model as human pediatric surrogate for preclinical pharmacokinetic and pharmacodynamic drug testing. Ghent University
Drug study designs adapted to the pediatric population are lacking up until now. The primary reason is the absence of representative preclinical methods and animal models that accurately reflect the age-based changes observed in infants. Because of the striking similarities in anatomy and physiology between humans and pigs, the suitability of pigs as a pediatric animal model will be evaluated.
Viruses are infectious pathogenic entities that use host elements to multiply and lead to a wide range of human diseases. Although antiviral drugs have previously been developed, for the last ten years very few new therapeutics have reached the market. This lack of progress is alarming since new viruses emerge and the well-known ones develop resistance rapidly, rendering the existing drugs ineffective. The intrinsic nature of viruses is ...
Based on a lead structure discovered in previous research a new class of drugs for the treatment of drug resistant epilepsy will be developed. Depending on biological evaluation results, the lead structure will be altered and equipped with different substituents in order to enhance its anticonvulsive properties. Numerous techniques will be combined to provide sufficient diversity to the lead structure so that an extensive structure-activity ...